PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8588913

Fluorescence-based method for selection of recombinant plasmids.

C A Roessner·A I Scott
View original source ↗Export metadata ↓

Abstract

A fluorescence-based method for the selection of recombinant plasmids has been developed. Escherichia coli strains bearing plasmids for the overexpression of the gene encoding uroporphyrinogen III methyltransferase (cobA or cysG gene) accumulate fluorescent porphyrinoid compounds. When illuminated with ultraviolet light, the cells fluoresce with a bright red color. Replacement or disruption of the gene with other fragments of DNA results in loss of enzymatic activity and nonfluorescent cells. The detection of the recombinant plasmids can be accomplished without special host strains or expensive chromogenic reagents required for the blue-white screening technique.

Explore related subjects

Aminolevulinic AcidDNA, RecombinantEscherichia coliFluorescenceGene ExpressionMethyltransferasesMolecular Sequence DataPlasmidsPolymerase Chain ReactionRestriction MappingSaccharomyces cerevisiaeSalmonella typhimuriumUltraviolet RaysResearch Support, U.S. Gov't, P.H.S.Technical ReportJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C A Roessner, A I Scott. 1995. Fluorescence-based method for selection of recombinant plasmids.. https://pubmed.ncbi.nlm.nih.gov/8588913/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval.

We have studied different single and fractionated illumination schemes after systemic administration of 5-aminolevulinic acid (ALA) to Improve the response of nodular tumors to ALA-mediated photodynamic therapy. Tumors transplanted on the thigh of female WAG/Rij rats were transdermally illuminated with red light (633 nm) after systemic ALA administration (200 mg/kg). The effectiveness of each treatment scheme was determined from the tumor volume doubling time. A single illumination (100 J/cm2 at 100 mW/cm2, 2.5 h after ALA administration) yielded a doubling time of 6.6+/-1.2 days. This was significantly different from the untreated control (doubling time, 1.7+/-0.1 days). The only treatment scheme that yielded a significant improvement compared to all other schemes studied was illumination at both 1 and 2.5 h after ALA administration (both 100 J/cm2 at 100 mW/cm2) and resulted in a tumor volume doubling time of 18.9+/-2.9 days. A possible mechanism to explain this phenomenon is that the protoporphyrin IX formed after administration of ALA is photodegraded by the first illumination. In the 75-min interval, new porphyrin is formed enhancing the effect of the second illumination.

Aminolevulinic Acid↗
PubMed1999

Plasma 5-aminolevulinic acid concentration and lead exposure in children.

The relationship between concentration of 5-aminolevulinic acid in plasma (ALAP) and other biomarkers of lead exposure and effect was investigated in lead-exposed children. We measured ALAP by chemical derivatization and high-performance liquid chromatography with fluorescence detection. The study population consisted of 103 children: 78 from a referral clinic for children with lead poisoning and 25 from a general pediatric clinic. Blood lead concentration (PbB), age, and ALAP were higher in lead clinic subjects than in general clinic subjects. ALAP was significantly correlated with PbB (Spearman r=0.38, P=0.0007) and free erythrocyte protoporphyrin concentration (r=0.41, P=0.0002) in lead clinic subjects. PbB was a significant predictor of ALAP (P=0.0001) by multiple linear regression in all subjects. The average PbB in the 3- to 12-month period prior to blood collection correlated with ALAP to the same degree that current PbB correlated with ALAP. Possible associations between ALAP and adverse health outcomes, particularly neurobehavioral effects, should be investigated in children to assess the predictive value of ALAP for these endpoints.

Aminolevulinic Acid↗